ArticleFrontiers in public health2025
Evolving landscape of female cancers along with attributable risk factors in China from 1990 to 2021, and projections to 2040.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Endometrial cancer mortality and its trends in China from 2004-2021.BMC cancer · 2026Article
- Burden and temporal trends of female-specific cancers in China: A systematic analysis of the 2023 global burden of disease study.PloS one · 2026Article
- Temporal Trends and Model-Based Projections of Female-Specific Cancer Burden Among East Asian Women Aged 55 Years and Older: A GBD 2023 Analysis.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Female cancers pose a significant health burden in China, and this study identified and projected epidemiological trends of these cancers. Methods: We extracted incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) data of female breast, cervical, uterine, and ovarian cancers in China from the Global Burden of Disease (GBD) Study 2021. The estimated annual percentage change (EAPC) and the age-period-cohort (APC) model were used to explore the trends, and the Bayesian APC model (BAPC) was employed to project the burden. Results: In 2021, breast cancer had the highest incidence (38.58 × 10 Conclusion: The female cancer burden in China has been rising and will continue to do so. Targeted prevention and intervention strategies are crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.